vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and i3 Verticals, Inc. (IIIV). Click either name above to swap in a different company.

4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $52.7M, roughly 1.6× i3 Verticals, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 0.9%, a 21.9% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -14.6%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $13.8M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -4.7%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

The Prusa i3 is a family of fused filament fabrication 3D printers, manufactured by Czech company Prusa Research under the trademarked name Original Prusa i3. Part of the RepRap project, Prusa i3 printers were called the most used 3D printer in the world in 2016. The first Prusa i3 was designed by Josef Průša in 2012, and was released as a commercial kit product in 2015. The latest model is available in both kit and factory assembled versions. The Prusa i3's comparable low cost and ease of co...

FDMT vs IIIV — Head-to-Head

Bigger by revenue
FDMT
FDMT
1.6× larger
FDMT
$85.1M
$52.7M
IIIV
Growing faster (revenue YoY)
FDMT
FDMT
+8508914.6% gap
FDMT
8508900.0%
-14.6%
IIIV
Higher net margin
FDMT
FDMT
21.9% more per $
FDMT
22.8%
0.9%
IIIV
More free cash flow
FDMT
FDMT
$14.7M more FCF
FDMT
$28.5M
$13.8M
IIIV
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
-4.7%
IIIV

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FDMT
FDMT
IIIV
IIIV
Revenue
$85.1M
$52.7M
Net Profit
$19.4M
$484.0K
Gross Margin
Operating Margin
17.3%
3.1%
Net Margin
22.8%
0.9%
Revenue YoY
8508900.0%
-14.6%
Net Profit YoY
139.1%
-76.5%
EPS (diluted)
$0.43
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
IIIV
IIIV
Q4 25
$85.1M
$52.7M
Q3 25
$90.0K
$46.0M
Q2 25
$15.0K
$51.9M
Q1 25
$14.0K
$63.1M
Q4 24
$1.0K
$52.2M
Q3 24
$3.0K
$32.0M
Q2 24
$5.0K
$46.2M
Q1 24
$28.0K
$58.0M
Net Profit
FDMT
FDMT
IIIV
IIIV
Q4 25
$19.4M
$484.0K
Q3 25
$-56.9M
$3.1M
Q2 25
$-54.7M
$12.9M
Q1 25
$-48.0M
$-154.0K
Q4 24
$2.1M
Q3 24
$-43.8M
$117.9M
Q2 24
$-35.0M
$-7.5M
Q1 24
$-32.4M
$1.9M
Operating Margin
FDMT
FDMT
IIIV
IIIV
Q4 25
17.3%
3.1%
Q3 25
-67983.3%
3.2%
Q2 25
-396373.3%
-9.3%
Q1 25
-383007.1%
8.0%
Q4 24
3.9%
Q3 24
-1704400.0%
10.6%
Q2 24
-849120.0%
-2.8%
Q1 24
-136200.0%
3.4%
Net Margin
FDMT
FDMT
IIIV
IIIV
Q4 25
22.8%
0.9%
Q3 25
-63195.6%
6.7%
Q2 25
-364386.7%
24.8%
Q1 25
-342657.1%
-0.2%
Q4 24
3.9%
Q3 24
-1461433.3%
368.2%
Q2 24
-699060.0%
-16.3%
Q1 24
-115717.9%
3.2%
EPS (diluted)
FDMT
FDMT
IIIV
IIIV
Q4 25
$0.43
$0.02
Q3 25
$-1.01
$0.14
Q2 25
$-0.98
$0.50
Q1 25
$-0.86
$0.00
Q4 24
$0.08
Q3 24
$-0.79
$4.93
Q2 24
$-0.63
$-0.32
Q1 24
$-0.66
$0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
IIIV
IIIV
Cash + ST InvestmentsLiquidity on hand
$402.7M
$37.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$505.7M
$358.5M
Total Assets
$566.7M
$595.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
IIIV
IIIV
Q4 25
$402.7M
$37.5M
Q3 25
$305.1M
$66.7M
Q2 25
$293.2M
$55.5M
Q1 25
$321.4M
$7.7M
Q4 24
$424.9M
$85.6M
Q3 24
$501.9M
$86.5M
Q2 24
$541.9M
$9.7M
Q1 24
$525.9M
$3.1M
Total Debt
FDMT
FDMT
IIIV
IIIV
Q4 25
Q3 25
$0
Q2 25
$0
Q1 25
$12.0M
Q4 24
$26.2M
Q3 24
$26.2M
Q2 24
$374.1M
Q1 24
$369.6M
Stockholders' Equity
FDMT
FDMT
IIIV
IIIV
Q4 25
$505.7M
$358.5M
Q3 25
$369.0M
$389.6M
Q2 25
$420.9M
$383.3M
Q1 25
$469.7M
$385.2M
Q4 24
$510.6M
$375.0M
Q3 24
$552.9M
$379.7M
Q2 24
$588.3M
$249.7M
Q1 24
$600.6M
$249.3M
Total Assets
FDMT
FDMT
IIIV
IIIV
Q4 25
$566.7M
$595.9M
Q3 25
$424.0M
$638.4M
Q2 25
$473.6M
$623.3M
Q1 25
$515.7M
$646.4M
Q4 24
$560.4M
$726.2M
Q3 24
$604.0M
$730.7M
Q2 24
$620.1M
$861.7M
Q1 24
$629.9M
$625.8M
Debt / Equity
FDMT
FDMT
IIIV
IIIV
Q4 25
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.03×
Q4 24
0.07×
Q3 24
0.07×
Q2 24
1.50×
Q1 24
1.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
IIIV
IIIV
Operating Cash FlowLast quarter
$28.6M
$14.1M
Free Cash FlowOCF − Capex
$28.5M
$13.8M
FCF MarginFCF / Revenue
33.5%
26.2%
Capex IntensityCapex / Revenue
0.1%
0.6%
Cash ConversionOCF / Net Profit
1.47×
29.18×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M
$6.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
IIIV
IIIV
Q4 25
$28.6M
$14.1M
Q3 25
$-46.5M
$14.0M
Q2 25
$-43.4M
$7.4M
Q1 25
$-47.8M
$-27.1M
Q4 24
$-134.6M
$11.5M
Q3 24
$-29.4M
$15.1M
Q2 24
$-30.2M
$8.1M
Q1 24
$-29.1M
$10.7M
Free Cash Flow
FDMT
FDMT
IIIV
IIIV
Q4 25
$28.5M
$13.8M
Q3 25
$-46.6M
$13.5M
Q2 25
$-43.4M
$6.8M
Q1 25
$-48.4M
$-27.6M
Q4 24
$-138.4M
$11.0M
Q3 24
$-31.2M
$14.6M
Q2 24
$-30.6M
$7.2M
Q1 24
$-29.8M
$9.9M
FCF Margin
FDMT
FDMT
IIIV
IIIV
Q4 25
33.5%
26.2%
Q3 25
-51765.6%
29.5%
Q2 25
-289620.0%
13.1%
Q1 25
-345635.7%
-43.8%
Q4 24
-13837100.0%
21.1%
Q3 24
-1038966.7%
45.6%
Q2 24
-611840.0%
15.6%
Q1 24
-106421.4%
17.1%
Capex Intensity
FDMT
FDMT
IIIV
IIIV
Q4 25
0.1%
0.6%
Q3 25
101.1%
0.9%
Q2 25
440.0%
1.0%
Q1 25
4507.1%
0.8%
Q4 24
378600.0%
0.9%
Q3 24
59266.7%
1.7%
Q2 24
6980.0%
1.9%
Q1 24
2535.7%
1.4%
Cash Conversion
FDMT
FDMT
IIIV
IIIV
Q4 25
1.47×
29.18×
Q3 25
4.52×
Q2 25
0.57×
Q1 25
Q4 24
5.59×
Q3 24
0.13×
Q2 24
Q1 24
5.72×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FDMT
FDMT

Segment breakdown not available.

IIIV
IIIV

License And Service$35.7M68%
Proprietary Payments Revenue$14.5M27%
Other Revenue$2.5M5%

Related Comparisons